149 related articles for article (PubMed ID: 26696392)
1. Generic switching of warfarin and risk of excessive anticoagulation: a Danish nationwide cohort study.
Hellfritzsch M; Rathe J; Stage TB; Thirstrup S; Grove EL; Damkier P; Pottegård A
Pharmacoepidemiol Drug Saf; 2016 Mar; 25(3):336-43. PubMed ID: 26696392
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and tolerability of the switch from a branded to a generic warfarin sodium product: an observer-blinded, randomized, crossover study.
Lee HL; Kan CD; Yang YJ
Clin Ther; 2005 Mar; 27(3):309-19. PubMed ID: 15878384
[TBL] [Abstract][Full Text] [Related]
3. Increased warfarin doses and decreased international normalized ratio response after nationwide generic switching.
Halkin H; Shapiro J; Kurnik D; Loebstein R; Shalev V; Kokia E
Clin Pharmacol Ther; 2003 Sep; 74(3):215-21. PubMed ID: 12966365
[TBL] [Abstract][Full Text] [Related]
4. Substitution of generic warfarin for Coumadin in an HMO setting.
Milligan PE; Banet GA; Waterman AD; Gatchel SK; Gage BF
Ann Pharmacother; 2002 May; 36(5):764-8. PubMed ID: 11978149
[TBL] [Abstract][Full Text] [Related]
5. Hemorrhagic and thrombotic events associated with generic substitution of warfarin in patients with atrial fibrillation: a retrospective analysis.
Ghate SR; Biskupiak JE; Ye X; Hagan M; Kwong WJ; Fox ES; Brixner DI
Ann Pharmacother; 2011 Jun; 45(6):701-12. PubMed ID: 21666081
[TBL] [Abstract][Full Text] [Related]
6. Resource use and cost implications of switching among warfarin formulations in atrial fibrillation patients.
Kwong WJ; Kamat S; Fang C
Ann Pharmacother; 2012 Dec; 46(12):1609-16. PubMed ID: 23150608
[TBL] [Abstract][Full Text] [Related]
7. Design and rationale for the WARFA trial: a randomized controlled cross-over trial testing the therapeutic equivalence of branded and generic warfarin in atrial fibrillation patients in Brazil.
Freitas CG; Walsh M; Atallah ÁN
BMC Cardiovasc Disord; 2017 Jun; 17(1):148. PubMed ID: 28592234
[TBL] [Abstract][Full Text] [Related]
8. Brand name versus generic warfarin: a systematic review of the literature.
Dentali F; Donadini MP; Clark N; Crowther MA; Garcia D; Hylek E; Witt DM; Ageno W;
Pharmacotherapy; 2011 Apr; 31(4):386-93. PubMed ID: 21449627
[TBL] [Abstract][Full Text] [Related]
9. The effect of generic switching on concerns about medicine and non-persistence among Danish adults in a general practice setting.
Rathe JØ
Dan Med J; 2015 Oct; 62(10):B5148. PubMed ID: 26441397
[TBL] [Abstract][Full Text] [Related]
10. Effect of heart failure exacerbations on anticoagulation: a prospective, observational, pilot cohort study.
Ripley TL; Harrison D; Germany RE; Adamson PB
Clin Ther; 2010 Mar; 32(3):506-14. PubMed ID: 20399987
[TBL] [Abstract][Full Text] [Related]
11. Completeness of prescription information in US commercial claims databases.
Lauffenburger JC; Balasubramanian A; Farley JF; Critchlow CW; O'Malley CD; Roth MT; Pate V; Brookhart MA
Pharmacoepidemiol Drug Saf; 2013 Aug; 22(8):899-906. PubMed ID: 23696101
[TBL] [Abstract][Full Text] [Related]
12. Bleeding events following concurrent use of warfarin and oseltamivir by Medicare beneficiaries.
Mosholder AD; Racoosin JA; Young S; Wernecke M; Shoaibi A; MaCurdy TE; Worrall C; Kelman JA
Ann Pharmacother; 2013 Nov; 47(11):1420-8. PubMed ID: 24285759
[TBL] [Abstract][Full Text] [Related]
13. [INTERNATIONAL NORMALIZED RATIO VALUES AND HEMORRHAGE IN HOSPITALIZED PATIENTS STARTING WARFARIN THERPY: AN OBSERVATIONAL STUDY].
Abadi U; Ellis MH
Harefuah; 2015 Aug; 154(8):490-3, 541-2. PubMed ID: 26480611
[TBL] [Abstract][Full Text] [Related]
14. Observational cohort study of switching warfarin sodium products in a managed care organization.
Swenson CN; Fundak G
Am J Health Syst Pharm; 2000 Mar; 57(5):452-5. PubMed ID: 10711525
[TBL] [Abstract][Full Text] [Related]
15. Subtherapeutic INR values associated with a switch to generic warfarin.
Hope KA; Havrda DE
Ann Pharmacother; 2001 Feb; 35(2):183-7. PubMed ID: 11215837
[TBL] [Abstract][Full Text] [Related]
16. Influence of kidney function on risk of supratherapeutic international normalized ratio-related hemorrhage in warfarin users: a prospective cohort study.
Limdi NA; Nolin TD; Booth SL; Centi A; Marques MB; Crowley MR; Allon M; Beasley TM
Am J Kidney Dis; 2015 May; 65(5):701-9. PubMed ID: 25468385
[TBL] [Abstract][Full Text] [Related]
17. Warfarin-antibiotic interactions in older adults of an outpatient anticoagulation clinic.
Ghaswalla PK; Harpe SE; Tassone D; Slattum PW
Am J Geriatr Pharmacother; 2012 Dec; 10(6):352-60. PubMed ID: 23089199
[TBL] [Abstract][Full Text] [Related]
18. Substituting warfarin products: what's the source of the problem?
Haines ST
Ann Pharmacother; 2011 Jun; 45(6):807-9. PubMed ID: 21666090
[TBL] [Abstract][Full Text] [Related]
19. The impact of pharmacist-managed oral anticoagulation therapy in older veterans.
Poon IO; Lal L; Brown EN; Braun UK
J Clin Pharm Ther; 2007 Feb; 32(1):21-9. PubMed ID: 17286786
[TBL] [Abstract][Full Text] [Related]
20. Risk factors for excessive anticoagulation among hospitalized adults receiving warfarin therapy using a pharmacist-managed dosing protocol.
Berg TM; O'Meara JG; Ou NN; Daniels PR; Moriarty JP; Bergstrahl EJ; Dierkhising RA; Manning DM
Pharmacotherapy; 2013 Nov; 33(11):1165-74. PubMed ID: 23625787
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
